This project tackles a challenging question in biology: how to reprogram human cells to become pluripotent stem cells (IPSCs) efficiently and safely. Reprogramming involves transforming specialized adult cells into IPSCs, potentially becoming any cell type, making them extremely promising in research and medicine. IPSCs could be used to repair damaged tissues or to model diseases in the lab for study. However, reprogramming is still a slow and complex process that doesn’t always yield high-quality results. Understanding the steps and specific gene networks involved is critical to improving the speed and reliability of this process.
Current reprogramming methods face several challenges. First, few cells fully complete reprogramming, and the remaining cells may not function correctly. Second, the genetic and epigenetic processes behind reprogramming aren’t completely understood. This lack of understanding means it’s difficult to know what exactly happens as cells move through different stages of reprogramming. The process is also risky, as unwanted mutations can arise, making cells less safe for therapeutic use.
This project addresses these challenges using advanced multi-omics techniques—analyzing the genes, proteins, and regulatory networks involved in reprogramming—to identify the intermediate states and factors influencing cellular transitions to pluripotency. This approach aims to gain better control over the reprogramming process, ensuring cells achieve full pluripotency without unintended side effects.
This research holds significant societal potential, particularly in regenerative medicine and personalized health care. The ability to produce high-quality IPSCs can transform treatment options for many conditions, such as neurodegenerative diseases, spinal cord injuries, and heart disease, by providing a source of cells that can repair damaged tissues. IPSCs could be used to replace damaged cells or tissues, potentially restoring function to organs that have been damaged by disease or injury.
Moreover, IPSCs provide a new way to study diseases in the lab. Traditional models often rely on animal studies, which don’t always accurately predict human responses to treatments. By creating patient-specific models using IPSCs, scientists can explore how different genetic backgrounds influence disease progression and drug responses, leading to more effective and targeted therapies. This also allows for faster, more ethical drug testing and development, as drugs can be tested directly on human cells.
The societal and economic impacts are also worth noting. Efficient and accessible reprogramming could make stem cell-based therapies more affordable, reaching a wider population. Additionally, research of this kind supports the biotech and healthcare sectors, creating new job opportunities and potential collaborations with the industry. This work also provides essential foundations for spin-offs, like NEGEDIA s.r.l. which focuses on using genomics in disease diagnosis. All of these developments contribute to advancing medical science and improving public health.
This project has four main goals, each addressing a core issue in cell reprogramming and aiming to make IPSCs a practical tool for therapeutic use.
The first objective is to identify and describe the intermediate cellular states during reprogramming. This means discovering what cell types appear as cells change and how these states affect the overall process. Understanding these states will help researchers control the transitions more precisely, moving cells toward pluripotency efficiently.
The second goal is to explore the regulatory networks of transcription factors (TFs) that guide the reprogramming process. Transcription factors are proteins that help control gene activity. Using techniques like MPRA (which tests how DNA segments promote gene expression) and scATACseq (which analyzes DNA accessibility in single cells), the project aims to identify the genes and regulatory pathways needed for successful reprogramming. This can help scientists refine reprogramming by focusing on key TFs that improve efficiency.
The third goal is to find and address "roadblocks" in reprogramming. These roadblocks can be mutations or gene regulation issues preventing cells from reprogramming. By comparing DNA in different reprogrammed cells, this project aims to pinpoint common mutations and genetic changes that act as barriers. Understanding these obstacles will allow scientists to modify protocols to minimize these issues, making the resulting cells safer for clinical use.
The fourth objective is to improve the quality of reprogrammed cells by developing new tools and methods. For example, using a microfluidic platform speeds up the testing and validation of candidate genes that may improve reprogramming outcomes. Using a scoring system (TERA score), the project will rank transcription factors based on their ability to guide cell identity changes, making the reprogramming process more predictable and controlled.
Overall, this project aims to create a valuable resource that maps key transcription factors, their targets, and the molecular pathways involved in reprogramming. By integrating all this data, the project not only advances our understanding of cell biology but also provides practical tools for developing effective cell-based therapies in the future.
